S

Sarepta Therapeutics
D

SRPT

16.825
USD
0.32
(1.94%)
قبل الجلسة·16.600USD-0.225(-1.34%)
حجم التداول
128,404
الربح لكل سهم
2
العائد الربحي
-
P/E
-11
حجم السوق
1,777,174,628
نظرة عامة
أصول ذات صلة
AMGN
AMGN
D
Amgen
426.14
13.26(3.21%)
418.63-7.51(-1.76%)
BIIB
BIIB
D
Biogen
232.950
4.020(1.76%)
230.000-2.950(-1.27%)
BMRN
BMRN
D
BioMarin Pharmaceutical
55.180
0.790(1.45%)
54.530-0.650(-1.18%)
EXEL
EXEL
D
Exelixis
61.020
1.510(2.54%)
GILD
GILD
D
Gilead Sciences
153.600
5.720(3.87%)
149.000-4.600(-2.99%)
INCY
INCY
D
Incyte Corp
111.620
3.060(2.82%)
107.720-3.900(-3.49%)
REGN
REGN
D
Regeneron Pharmaceuticals
779.27
25.98(3.45%)
VRTX
VRTX
D
Vertex Pharmaceuticals
498.50
13.44(2.77%)
المزيد

العنوان: Sarepta Therapeutics

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.